<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01512979</url>
  </required_header>
  <id_info>
    <org_study_id>1218.83</org_study_id>
    <secondary_id>2011-004158-24</secondary_id>
    <nct_id>NCT01512979</nct_id>
  </id_info>
  <brief_title>Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes</brief_title>
  <official_title>A 24-week, Randomized, Double-blind, Active-controlled, Parallel Group Trial to Assess the Superiority of Oral Linagliptin and Metformin Compared to Linagliptin Monotherapy in Newly Diagnosed, Treatment-naïve, Uncontrolled Type 2 Diabetes Mellitus Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine whether a initial combination of linagliptin and
      metformin compared to linagliptin alone for 24 weeks is effective in newly diagnosed,
      treatment-naïve patients with Type 2 Diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in HbA1c After 24 Weeks</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>HbA1c is measured as a percentage. The change from baseline is the Week 24 HbA1c minus the baseline HbA1c. Means are adjusted for treatment and continuous baseline HbA1c</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) After 24 Weeks of Treatment</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>The change from baseline is the FPG after 24 weeks minus the baseline FPG. Means are adjusted for treatment, continuous baseline HbA1c and continuous baseline fasting plasma glucose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HbA1c by Visit Over Time</measure>
    <time_frame>Baseline, 6, 12, 18 and 24 weeks</time_frame>
    <description>HbA1c is measured as a percentage. The change from baseline is the HbA1c over time minus the baseline HbA1c. The model includes treatment, continuous baseline HbA1c in addition to week repeated within patient, week by baseline HbA1c interaction and week by treatment interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5% After 24 Weeks of Treatment)</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>The proportion of patients who achieved HbA1c lowering by at least 0.5% after 24 weeks of treatment.The model includes treatment, and continuous baseline HbA1c.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 1.0% After 24 Weeks of Treatment)</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>The proportion of patients who achieved HbA1c lowering by at least 1.0% after 24 weeks of treatment. The model includes treatment, and continuous baseline HbA1c.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Treat to Target Efficacy Response (HbA1c &lt;7.0%) After 24 Weeks of Treatment</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>The proportion of patients who achieved HbA1c below 7.0% after 24 weeks of treatment. The model includes treatment, and continuous baseline HbA1c.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FPG by Visit Over Time</measure>
    <time_frame>Baseline, 6, 12, 18 and 24 weeks</time_frame>
    <description>The change from baseline is the FPG over time minus the baseline FPG. Means are adjusted for treatment, continuous baseline HbA1c, continuous baseline FPG in addition to week repeated within patient, week by baseline FPG interaction and week by treatment interaction.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">316</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>linagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients receive linagliptin tablet once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>linagliptin plus metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients receive linagliptin tablet once daily and metformin tablets twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>1000 mg to 2000 mg per day</description>
    <arm_group_label>linagliptin plus metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>linagliptin</intervention_name>
    <description>5 mg daily</description>
    <arm_group_label>linagliptin</arm_group_label>
    <arm_group_label>linagliptin plus metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin placebo</intervention_name>
    <description>0 to 2 tablets daily</description>
    <arm_group_label>linagliptin plus metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin placebo</intervention_name>
    <description>4 tablets daily</description>
    <arm_group_label>linagliptin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Patients must sign and date an Informed Consent consistent with International
             Conference on Harmonisation / Good Clinical Practice guidelines and local regulations
             prior to any evaluation and participation in the trial.

          2. Male and female patients, 18 years of age or older at Visit 1 (Screen), with newly
             diagnosed (less than 12 months prior to Screen) Type 2 Diabetes Mellitus.

          3. Patients who are treatment-naïve, defined as absence of any oral antidiabetic therapy,
             injectable glucagon-like peptide-1 agonist/analogue, or insulin, and uncontrolled for
             the 12 weeks prior to randomisation.

          4. Patients must have an glycated (or glycosylated) haemoglobin (HbA1c) between 8.5% [69
             millimoles per mole (mmol/mol)] and 12.0% (108 mmol/mol) at Visit 1 (Screen).

          5. Patients must have a Body Mass Index (BMI) of 45 kg/m2 or less at Visit 1 (Screen).

          6. In the investigators opinion, patients must be reliable, honest, compliant, and agree
             to cooperate with all planned future trial evaluations as explained in detail during
             the informed consent process and to be able to perform them.

        Exclusion criteria:

        Patients with, who are, who have, or who have had:

          1. Acute coronary syndrome (non-ST Elevation Myocardial Infarction (STEMI), STEMI, and
             unstable angina pectoris), stroke or transient ischemic attack within 3 months prior
             to informed consent.

          2. Indication of liver disease determined during Screen and/or Run-In Period, defined by
             a serum level above 3 times the upper limit of normal (ULN) in any of the following:
             alanine aminotransferase, aspartate aminotransferase, or alkaline phosphatase.
             Gilbert-Meulengracht syndrome (also known as conjugated hyperbilirubinemia,
             constitutional hepatic dysfunction, or familial nonhemolytic jaundice) will be
             permitted.

          3. Impaired renal function, defined as calculated creatinine clearance of less than 60
             milliliters per minute (&lt; 60 mL/min), by the Cockcroft-Gault Equation, as determined
             during Screen and/or Run-In Period.

          4. Bariatric, gastric bypass, and other gastrointestinal surgeries (including all types
             of gastric banding and/or LapBand) within the past two years.

          5. Medical history of cancer (except for basal cell carcinoma) and/or treatment for
             cancer within the last 5 years.

          6. Medical history of pancreatitis.

          7. Blood dyscrasias or any disorders causing hemolysis or unstable red blood cells (e.g.,
             malaria, babesiosis, haemolytic anaemia).

          8. Any contraindication to metformin and/or linagliptin therapies, according to local
             labels.

          9. Treatment with anti-obesity drugs, including over-the-counter drugs such as Alli
             (orlistat), 3 months prior to informed consent or any other treatment at the time of
             screening (i.e., surgery, aggressive diet regimen, etc.) leading to unstable body
             weight.

         10. Current treatment with systemic steroids at time of informed consent or change in
             dosage of thyroid hormones within 6 weeks prior to informed consent or any other
             uncontrolled endocrine disorder except Type 2 Diabetes Mellitus.

         11. Pre-menopausal women (last menstruation of 1 year or less prior to informed consent)
             who are nursing or pregnant, are of child-bearing potential and are not practicing an
             acceptable method of birth control, or do not plan to continue using this method
             throughout the trial and do not agree to submit to periodic pregnancy testing during
             participation in the trial.

             Note: Acceptable methods of birth control include tubal ligation, transdermal patch,
             intra uterine devices/systems, oral, implantable, intra-vaginal, or injectable
             contraceptives, Essure micro-inserts placed more than six months prior to Screen
             Visit, complete sexual abstinence (if acceptable by local authorities), double barrier
             method (e.g., diaphragm or condom and spermicide), and vasectomised partner.

         12. Alcohol or drug abuse within the 3 months prior to informed consent that would
             interfere with trial participation or any ongoing condition leading to decreased
             compliance to trial procedures or study medication intake in the opinion of the
             investigator.

         13. Participation in another trial with an investigational drug within 2 months prior to
             informed consent.

         14. Any other clinical condition that would jeopardize patient safety while participating
             in this clinical trial in the opinion of the Investigator.

         15. Inability to commit to regular overnight fasting of at least 10 hours duration and
             attendance to study site visits between 07:00 and 11:00 ante meridiem (a.m.).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1218.83.11002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.11036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.11011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chino</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.11001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.11019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.11015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lomita</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.11023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Norwalk</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.11014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.11031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.11022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.11025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.11033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sanford</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.11029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oakwood</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.11026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.11008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Elkton</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.11027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Freemont</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.11005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.11013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.11028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.11009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shelby</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.11003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Franklin</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.11024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gallipolis</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.11018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.11004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.11017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.11032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Grand Prairie</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.11030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.11034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.11021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.12011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.12007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.12001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Red Deer</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.12002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paradise</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.12009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.12005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.12006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.12003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Smiths Falls</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.12010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.12012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.91003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.91005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.91001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.97004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.97005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.97007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Holon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.60001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kelantan</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.60002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Perak</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.60003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Selangor, Malaysia</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.52004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cuautla</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.52001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.52002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.52005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Merida</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.52003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tampico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.63007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cebu City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.63001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cebu</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.63008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Iloilo City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.63003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Iloilo</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.63002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marikina City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.63006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marikina City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.63004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quezon</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.11037 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.07001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.07002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Petrozavodsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.07004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.07006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Smolensk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.07003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.07007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.07005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.94004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dehiwela</city>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.94002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Galle, Sri Lanka</city>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.94003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kandy</city>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.94001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ragama</city>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.66002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.66003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.66001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Muang, Khonkaen</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.38007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dnepropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.38001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.38006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.38004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Odessa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.38008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vinnitsa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.38003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vinnytsya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1218.83.38005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vinnytsya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>India</country>
    <country>Israel</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Philippines</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>Sri Lanka</country>
    <country>Thailand</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Guatemala</country>
  </removed_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2012</study_first_submitted>
  <study_first_submitted_qc>January 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2012</study_first_posted>
  <results_first_submitted>April 8, 2014</results_first_submitted>
  <results_first_submitted_qc>April 8, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 9, 2014</results_first_posted>
  <last_update_submitted>May 12, 2014</last_update_submitted>
  <last_update_submitted_qc>May 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Linagliptin 5mg + Metformin</title>
          <description>Patients treated with linagliptin 5mg and metformin IR (1500mg to 2000mg total daily dose)</description>
        </group>
        <group group_id="P2">
          <title>Linagliptin 5mg</title>
          <description>Patients treated with linagliptin 5mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="159">Randomised and treated</participants>
                <participants group_id="P2" count="157">Randomised and treated</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
                <participants group_id="P2" count="135"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason other than stated above</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients from Treated Set (TS): All patients treated with at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Linagliptin 5mg + Metformin</title>
          <description>Patients treated with linagliptin 5mg and metformin IR (1500mg to 2000mg total daily dose)</description>
        </group>
        <group group_id="B2">
          <title>Linagliptin 5mg</title>
          <description>Patients treated with linagliptin 5mg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="159"/>
            <count group_id="B2" value="157"/>
            <count group_id="B3" value="316"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.0" spread="10.9"/>
                    <measurement group_id="B2" value="48.6" spread="11.2"/>
                    <measurement group_id="B3" value="48.8" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline HbA1c</title>
          <description>Baseline HbA1c was analyzed for the Full Analysis Set which includes all patients randomised, treated with at least 1 dose of study drug, with a baseline HbA1c value and at least 1 on-treatment HbA1c value. The Linagliptin 5mg + Metformin group includes 153 participants, the Linagliptin 5mg group includes 150 participants (303 participants in total).</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.79" spread="1.19"/>
                    <measurement group_id="B2" value="9.88" spread="1.10"/>
                    <measurement group_id="B3" value="9.83" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in HbA1c After 24 Weeks</title>
        <description>HbA1c is measured as a percentage. The change from baseline is the Week 24 HbA1c minus the baseline HbA1c. Means are adjusted for treatment and continuous baseline HbA1c</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>Per Protocol completers cohort (PPCC): All patients randomised, treated with at least 1 dose of study drug, with a baseline HbA1c value without important protocol violations and who completed 24 weeks of treatment, were not treated with rescue medication and have an HbA1c measurement after 24 weeks of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin 5mg + Metformin</title>
            <description>Patients treated with linagliptin 5mg and metformin IR (1500mg to 2000mg total daily dose)</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 5mg</title>
            <description>Patients treated with linagliptin 5mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c After 24 Weeks</title>
          <description>HbA1c is measured as a percentage. The change from baseline is the Week 24 HbA1c minus the baseline HbA1c. Means are adjusted for treatment and continuous baseline HbA1c</description>
          <population>Per Protocol completers cohort (PPCC): All patients randomised, treated with at least 1 dose of study drug, with a baseline HbA1c value without important protocol violations and who completed 24 weeks of treatment, were not treated with rescue medication and have an HbA1c measurement after 24 weeks of treatment.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.81" spread="0.12"/>
                    <measurement group_id="O2" value="-2.02" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The model includes treatment and continuous baseline HbA1c.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.79</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.13</ci_lower_limit>
            <ci_upper_limit>-0.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) After 24 Weeks of Treatment</title>
        <description>The change from baseline is the FPG after 24 weeks minus the baseline FPG. Means are adjusted for treatment, continuous baseline HbA1c and continuous baseline fasting plasma glucose.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>Patients from PPCC (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin 5mg + Metformin</title>
            <description>Patients treated with linagliptin 5mg and metformin IR (1500mg to 2000mg total daily dose)</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 5mg</title>
            <description>Patients treated with linagliptin 5mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG) After 24 Weeks of Treatment</title>
          <description>The change from baseline is the FPG after 24 weeks minus the baseline FPG. Means are adjusted for treatment, continuous baseline HbA1c and continuous baseline fasting plasma glucose.</description>
          <population>Patients from PPCC (LOCF)</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-47.1" spread="3.8"/>
                    <measurement group_id="O2" value="-30.2" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0032</p_value>
            <p_value_desc>The model includes treatment, continuous baseline HbA1c and continuous baseline FPG.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-16.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-28.0</ci_lower_limit>
            <ci_upper_limit>-5.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HbA1c by Visit Over Time</title>
        <description>HbA1c is measured as a percentage. The change from baseline is the HbA1c over time minus the baseline HbA1c. The model includes treatment, continuous baseline HbA1c in addition to week repeated within patient, week by baseline HbA1c interaction and week by treatment interaction.</description>
        <time_frame>Baseline, 6, 12, 18 and 24 weeks</time_frame>
        <population>Patients from PPCC (observed cases)</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin 5mg + Metformin</title>
            <description>Patients treated with linagliptin 5mg and metformin IR (1500mg to 2000mg total daily dose)</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 5mg</title>
            <description>Patients treated with linagliptin 5mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c by Visit Over Time</title>
          <description>HbA1c is measured as a percentage. The change from baseline is the HbA1c over time minus the baseline HbA1c. The model includes treatment, continuous baseline HbA1c in addition to week repeated within patient, week by baseline HbA1c interaction and week by treatment interaction.</description>
          <population>Patients from PPCC (observed cases)</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change to week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.97" spread="0.09"/>
                    <measurement group_id="O2" value="-1.33" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.69" spread="0.11"/>
                    <measurement group_id="O2" value="-1.85" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.79" spread="0.11"/>
                    <measurement group_id="O2" value="-2.01" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.81" spread="0.12"/>
                    <measurement group_id="O2" value="-2.01" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5% After 24 Weeks of Treatment)</title>
        <description>The proportion of patients who achieved HbA1c lowering by at least 0.5% after 24 weeks of treatment.The model includes treatment, and continuous baseline HbA1c.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>Patients from PPCC. Non-completers considered as failures.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin 5mg + Metformin</title>
            <description>Patients treated with linagliptin 5mg and metformin IR (1500mg to 2000mg total daily dose)</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 5mg</title>
            <description>Patients treated with linagliptin 5mg</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5% After 24 Weeks of Treatment)</title>
          <description>The proportion of patients who achieved HbA1c lowering by at least 0.5% after 24 weeks of treatment.The model includes treatment, and continuous baseline HbA1c.</description>
          <population>Patients from PPCC. Non-completers considered as failures.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0031</p_value>
            <p_value_desc>The model includes treatment and continuous baseline HbA1c.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.830</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.573</ci_lower_limit>
            <ci_upper_limit>9.328</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 1.0% After 24 Weeks of Treatment)</title>
        <description>The proportion of patients who achieved HbA1c lowering by at least 1.0% after 24 weeks of treatment. The model includes treatment, and continuous baseline HbA1c.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>Patients from PPCC. Non-completers considered as failures.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin 5mg + Metformin</title>
            <description>Patients treated with linagliptin 5mg and metformin IR (1500mg to 2000mg total daily dose)</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 5mg</title>
            <description>Patients treated with linagliptin 5mg</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 1.0% After 24 Weeks of Treatment)</title>
          <description>The proportion of patients who achieved HbA1c lowering by at least 1.0% after 24 weeks of treatment. The model includes treatment, and continuous baseline HbA1c.</description>
          <population>Patients from PPCC. Non-completers considered as failures.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0025</p_value>
            <p_value_desc>The model includes treatment and continuous baseline HbA1c.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.920</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.458</ci_lower_limit>
            <ci_upper_limit>5.849</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Treat to Target Efficacy Response (HbA1c &lt;7.0%) After 24 Weeks of Treatment</title>
        <description>The proportion of patients who achieved HbA1c below 7.0% after 24 weeks of treatment. The model includes treatment, and continuous baseline HbA1c.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>Patients from PPCC. Non-completers considered as failures.</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin 5mg + Metformin</title>
            <description>Patients treated with linagliptin 5mg and metformin IR (1500mg to 2000mg total daily dose)</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 5mg</title>
            <description>Patients treated with linagliptin 5mg</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Treat to Target Efficacy Response (HbA1c &lt;7.0%) After 24 Weeks of Treatment</title>
          <description>The proportion of patients who achieved HbA1c below 7.0% after 24 weeks of treatment. The model includes treatment, and continuous baseline HbA1c.</description>
          <population>Patients from PPCC. Non-completers considered as failures.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0008</p_value>
            <p_value_desc>The model includes treatment and continuous baseline HbA1c.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.448</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.453</ci_lower_limit>
            <ci_upper_limit>4.123</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FPG by Visit Over Time</title>
        <description>The change from baseline is the FPG over time minus the baseline FPG. Means are adjusted for treatment, continuous baseline HbA1c, continuous baseline FPG in addition to week repeated within patient, week by baseline FPG interaction and week by treatment interaction.</description>
        <time_frame>Baseline, 6, 12, 18 and 24 weeks</time_frame>
        <population>Patients from PPCC, Observed Cases</population>
        <group_list>
          <group group_id="O1">
            <title>Linagliptin 5mg + Metformin</title>
            <description>Patients treated with linagliptin 5mg and metformin IR (1500mg to 2000mg total daily dose)</description>
          </group>
          <group group_id="O2">
            <title>Linagliptin 5mg</title>
            <description>Patients treated with linagliptin 5mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FPG by Visit Over Time</title>
          <description>The change from baseline is the FPG over time minus the baseline FPG. Means are adjusted for treatment, continuous baseline HbA1c, continuous baseline FPG in addition to week repeated within patient, week by baseline FPG interaction and week by treatment interaction.</description>
          <population>Patients from PPCC, Observed Cases</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change to week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-52.3" spread="3.37"/>
                    <measurement group_id="O2" value="-31.9" spread="3.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-54.1" spread="3.49"/>
                    <measurement group_id="O2" value="-30.5" spread="3.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-52.4" spread="3.20"/>
                    <measurement group_id="O2" value="-35.4" spread="3.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-47.1" spread="3.88"/>
                    <measurement group_id="O2" value="-30.1" spread="4.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 28 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Linagliptin 5mg + Metformin</title>
          <description>Patients treated with linagliptin 5mg and metformin IR (1500mg to 2000mg total daily dose)</description>
        </group>
        <group group_id="E2">
          <title>Linagliptin 5mg</title>
          <description>Patients treated with linagliptin 5mg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Umbilical hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

